Stock Detail
ANTHERA PHARMACEUTICALS INC
Sector: Biotechnology
Latest Quote @ Wed Jun 6 20:32:17 (15 min delayed)
| N/A |
N/A |
$0.5605 |
-0.0155 |
-2.69% |
|
Last Day's Data
| $0.58 |
$0.58 |
$0.01 |
1.75% |
0.00 |
$0.57 |
| $0.58 |
$0.56 |
169,895.00 |
86.84M |
735,192.00 |
0.00 |
Pivot Table
| R2 |
R1 |
Pivot |
S1 |
S2 |
| 0.59 |
0.58 |
0.57 |
0.56 |
0.55 |
Stock Profile
Anthera Pharmaceuticals, Inc., a development stage biopharmaceutical company, focuses on developing and commercializing therapeutics to treat diseases associated with inflammation, including cardiovascular and autoimmune diseases. Its primary product candidates include varespladib methyl (A-002), which has completed its Phase 2 clinical studies for the treatment of acute coronary syndrome; varespladib sodium (A-001) that is in a Phase 2 clinical study for the prevention of acute chest syndrome associated with sickle cell disease; and A-623, which has completed Phase 1 clinical studies for the treatment of B-cell mediated autoimmune diseases. The company has license agreements with Eli Lilly and Company, and Shionogi & Co., Ltd. to develop and commercialize secretory phospholipase A2 or sPLA2 inhibitors for the treatment of cardiovascular disease and other diseases; and Amgen Inc., to develop and commercialize A-623. Anthera Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Hayward, California.
